Compare Mesoblast Limited (MESO) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Advanced Drainage Systems Inc — how do they compare? Mesoblast Limited trades at $16.83 (market cap $2.21B), while Advanced Drainage Systems Inc trades at $140.99 (market cap $10.83B). The key difference: Advanced Drainage Systems Inc is far larger — about 4.9× Mesoblast Limited's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WMS | |
|---|---|---|
Market Cap | $2.21B | $10.83B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $175.38 |
52-Week Low | $12.88 | $129.50 |
Enterprise Value | $2.21B | $12.44B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Advanced Drainage Systems (WMS) trades at $140.13, down 1.09% on the day, amid a bearish technical signal from moving averages. The company demonstrates strong profitability with a 14% net income margin and 24.9% ROE, supported by recent earnings beats. Revenue for fiscal 2025 was $2.90 billion, with cash flow from operations at $581.49 million. Analyst consensus is a Buy with a $185.86 price target, indicating significant upside potential from current levels.
The outlook for WMS is positive based on solid fundamentals and analyst optimism, though near-term technical weakness and competitive pressures pose risks. Investment appeal centers on earnings growth and market leadership in water management solutions, balanced by exposure to construction sector volatility and rising debt levels noted in 2026 projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
